JO3737B1 - تركيبات علاجية من باكليتاكسيل تعطى عن طريق الفم ومثبط P-gp لعلاج السرطان - Google Patents

تركيبات علاجية من باكليتاكسيل تعطى عن طريق الفم ومثبط P-gp لعلاج السرطان

Info

Publication number
JO3737B1
JO3737B1 JOP/2016/0149A JOP20160149A JO3737B1 JO 3737 B1 JO3737 B1 JO 3737B1 JO P20160149 A JOP20160149 A JO P20160149A JO 3737 B1 JO3737 B1 JO 3737B1
Authority
JO
Jordan
Prior art keywords
cancer
inhibitor
treatment
orally administered
administered paclitaxel
Prior art date
Application number
JOP/2016/0149A
Other languages
English (en)
Inventor
Min-Fun Rudolf Kwan
Paul William Glue
Cheung-Tak Hung
E Douglas Kramer
Jr Gerald J Fetterly
Christopher Glyn Charles Alexander Jackson
Original Assignee
Athenex Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Athenex Therapeutics Ltd filed Critical Athenex Therapeutics Ltd
Application granted granted Critical
Publication of JO3737B1 publication Critical patent/JO3737B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

<span dir="RTL">يتعلق الطلب الحالي بتركيبات دوائية لجرعة من علاج باكليتاكسيل عن طريق الفم ومثبط </span>P-GP<span dir="RTL"> هذه التركيبات الدوائية مناسبة لعلاج السرطان في مستهدف بالعلاج للحد من أو لمنع تفاعلات السمية أو نقيع فرط الحساسية والنتائج السلبية الأخرى الناتجة عن أو المترافقة مع إعطاء جرعة من باكليتاكسيل تعطى عن طريق الوريد (على سبيل المثال، </span>Taxol®<span dir="RTL"> أو باكليتاكسيل يتم صياغته مع </span>Cremophor®<span dir="RTL"> لعلاج مستهدف يعاني من مرض السرطان</span>
JOP/2016/0149A 2015-07-21 2016-07-20 تركيبات علاجية من باكليتاكسيل تعطى عن طريق الفم ومثبط P-gp لعلاج السرطان JO3737B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562195243P 2015-07-21 2015-07-21

Publications (1)

Publication Number Publication Date
JO3737B1 true JO3737B1 (ar) 2021-01-31

Family

ID=57833861

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2016/0149A JO3737B1 (ar) 2015-07-21 2016-07-20 تركيبات علاجية من باكليتاكسيل تعطى عن طريق الفم ومثبط P-gp لعلاج السرطان

Country Status (9)

Country Link
US (2) US20180207148A1 (ar)
EP (1) EP3324968B1 (ar)
CN (2) CN108135895A (ar)
AU (3) AU2016295357B2 (ar)
CA (1) CA2993127C (ar)
JO (1) JO3737B1 (ar)
MX (2) MX389270B (ar)
TW (1) TWI760306B (ar)
WO (1) WO2017013490A2 (ar)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI715636B (zh) * 2015-09-30 2021-01-11 香港商慧源香港創新有限公司 口服紫杉烷組合物及方法
CN112351779A (zh) * 2018-04-13 2021-02-09 慧源医疗有限公司 用于治疗血管肉瘤的口服给药紫杉醇和P-gp抑制剂的治疗组合
AU2019395284B2 (en) * 2018-12-14 2025-07-17 Health Hope Pharma Hk Limited Therapeutic combinations of orally administered irinotecan and a P-gp inhibitor for the treatment of cancer
EP4398899A1 (en) * 2021-09-10 2024-07-17 Athenex, Inc. Therapeutic combinations of orally administered paclitaxel, a p-gp inhibitor, and a checkpoint inhibitor for the treatment of solid tumors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968972A (en) * 1995-10-26 1999-10-19 Baker Norton Pharmaceuticals, Inc. Method for increasing the oral bioactivity of pharmaceutical agents
MXPA02004164A (es) * 1999-10-27 2002-10-17 Baker Norton Pharma Metodo y composiciones para administrar taxanos por via oral a pacientes humanos.
JP2005528418A (ja) * 2002-05-07 2005-09-22 アルタナ　ファルマ　アクチエンゲゼルシャフト 気道疾患を治療するための新規組み合わせ
KR100557093B1 (ko) * 2003-10-07 2006-03-03 한미약품 주식회사 다약제 내성 저해 활성을 갖는 테트라졸 유도체 및 그의제조방법
KR101466245B1 (ko) * 2010-01-15 2014-12-01 한미사이언스 주식회사 테트라졸 메탄설폰산 염의 제조방법 및 이에 사용되는 신규 화합물
US10441544B2 (en) * 2017-10-10 2019-10-15 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation
CN112351779A (zh) * 2018-04-13 2021-02-09 慧源医疗有限公司 用于治疗血管肉瘤的口服给药紫杉醇和P-gp抑制剂的治疗组合

Also Published As

Publication number Publication date
EP3324968B1 (en) 2023-09-27
US20230172926A1 (en) 2023-06-08
MX2022000394A (es) 2022-02-10
AU2023229590A1 (en) 2023-10-05
AU2021209160A1 (en) 2021-08-19
TW201716064A (zh) 2017-05-16
MX389270B (es) 2025-03-20
AU2016295357B2 (en) 2021-05-13
CN108135895A (zh) 2018-06-08
EP3324968A2 (en) 2018-05-30
CA2993127A1 (en) 2017-01-26
WO2017013490A3 (en) 2017-03-02
WO2017013490A2 (en) 2017-01-26
AU2016295357A1 (en) 2018-02-15
TWI760306B (zh) 2022-04-11
US20180207148A1 (en) 2018-07-26
NZ739270A (en) 2024-10-25
CA2993127C (en) 2023-10-17
CN115778956A (zh) 2023-03-14
MX2018000872A (es) 2018-08-15
HK1256017A1 (en) 2019-09-13
EP3324968A4 (en) 2019-04-10
EP3324968C0 (en) 2023-09-27

Similar Documents

Publication Publication Date Title
MX2023000796A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
MX2021003230A (es) Composiciones farmaceuticas que comprenden meloxicam.
GT201700167A (es) Terapias de combinación para el tratamiento de cánceres.
TW201613887A (en) Antiproliferative compounds and methods of use thereof
NI201400095A (es) Metodos para el tratamiento del cáncer de pulmon de celulas no pequeñas utilizando terapia combinada de inhibidor tor cinasa.
MX2015010791A (es) Metodos para tratar el cancer y prevenir la resistencia a farmacos.
PH12015502616A1 (en) Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
MX2017017138A (es) Conjugados homogeneos especificos de sitio con inhibidores de ksp.
PH12020550462A1 (en) Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
HK1255141A1 (zh) 包含抗folr1免疫缀合物的治疗组合
MX381440B (es) Composicion farmaceutica para tratar colitis ulcerativa.
NZ716765A (en) Pharmaceutical combinations for the treatment of cancer
PH12017502046A1 (en) Salts and prodrugs of 1-methyl-d-tryptophan
MX2022000394A (es) Combinaciones terapeuticas de paclitaxel oralmente administrado y un inhibidor de la bomba de p-glicoproteina (p-gp) para el tratamiento del cancer.
UA118474C2 (uk) (s)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині
BR102012028120B8 (pt) Uso de um ou mais derivados de ingenol, composição farmacêutica e medicamento
CO6761366A2 (es) Composiciones farmacéuticas para el tratamiento de glioma maligno
MX381526B (es) Agente para suprimir el progreso de o para mejorar la enfermedad renal crónica.
CY1119522T1 (el) (r)- πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
UY35033A (es) Formulación en comprimidos de un inhibidor de la fosfatidilinositol 3-cinasa
UA95037U (uk) Спосіб лікування неалкогольного стеатогепатиту
UA104733U (uk) Спосіб лікування гастропатій у пацієнтів з хронічним обструктивним захворюванням легень
HK1204956A1 (zh) 癌症治療